Gregory Austin Ciongoli

Executive

Atara Biotherapeutics, Inc.Zymeworks Inc.REGENXBIO Inc.

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 2 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€814k

▼ Sales (0 ops.)

—

Latest filing published 27 Aug 2026 for REGENXBIO Inc..

Filing timeline

BuySale

Gregory Austin Ciongoli

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Gregory Austin Ciongoli: trading record in brief

Gregory Austin Ciongoli discloses dealings in 3 companies, chiefly REGENXBIO Inc., Atara Biotherapeutics, Inc. and Zymeworks Inc. The record holds 5 filings, for trades running from 12 August 2025 to 27 August 2026.

On the market, this insider has only ever bought: 2 purchases, €814k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 3 share grants. 2026 to date brings 2 purchases and no sales.

The latest filing, published on 27 August 2026, reports a share grant in REGENXBIO Inc. The clock since the last published purchase (27 August 2026) now reads 58 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.